Luteal estradiol administration strengthens the relationship between day 3 follicle- stimulating hormone and inhibin B levels and ovarian follicular status

Slides:

Advertisements

Similar presentations

Clarisa R. Gracia, M. D. , M. S. C. E. , Christopher B. Morse, B. A

Advertisements

Elevated serum progesterone-to-estradiol ratio during gonadotropin stimulation for intrauterine insemination or in vitro fertilization is not associated.

Evaluation of the relationship between follicular fluid oxidative stress, ovarian hormones, and response to gonadotropin stimulation Malathy Appasamy,

New look at endometrial echogenicity: objective computer-assisted measurements predict endometrial receptivity in in vitro fertilization–embryo transfer

Variation in circulating antimüllerian hormone precursor during the periovulatory and acute postovulatory phases of the human ovarian cycle Michael W.

Human chorionic gonadotropin administration does not increase plasma androgen levels in patients undergoing controlled ovarian hyperstimulation Renato.

Clarisa R. Gracia, M. D. , M. S. C. E. , Christopher B. Morse, B. A

Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection.

Elevated serum progesterone-to-estradiol ratio during gonadotropin stimulation for intrauterine insemination or in vitro fertilization is not associated.

Follicular and endocrine response to anastrozole versus clomiphene citrate administered in follicular phase to normoovulatory women: a randomized comparison

Predictors of poor ovarian response in in vitro fertilization: a prospective study comparing basal markers of ovarian reserve László F.J.M.M Bancsi,

Letrozole administration during the luteal phase after ovarian stimulation impacts corpus luteum function: a randomized, placebo-controlled trial Juan.

Value of the serum estradiol level for preventing ovarian hyperstimulation syndrome: a retrospective case control study Arianna D'Angelo, M.D., Rachel.

Increasing uterine receptivity by decreasing estradiol levels during the preimplantation period in high responders with the use of a follicle-stimulating.

James P Toner, M.D., Ph.D. Fertility and Sterility

Antimüllerian hormone levels decrease in women using combined contraception independently of administration route Sanna Kallio, M.D., Johanna Puurunen,

The menopausal transition

The luteal phase of recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization cycles during supplementation.

Cem Atabekoglu, M. D. , Murat Sonmezer, M. D. , Sinan Özkavukcu, M. D

Hongxia Li, M. D. , Jiangang Chen, M. D. , James W Overstreet, M. D

Serum antimüllerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids Isabelle.

Effects of vaginal progesterone administration on uterine contractility at the time of embryo transfer Renato Fanchin, M.D., Claudia Righini, M.D., Dominique.

Hakan Cakmak, M. D. , Audra Katz, R. N. , Marcelle I. Cedars, M. D

Zeev Shoham, M.D. Fertility and Sterility

Occurrence of postmenopausal-like acidic follicle-stimulating hormone (FSH) isoforms precedes the rise of FSH before menopause Chris M.G. Thomas, Ph.D.,

A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data

Improved monofollicular ovulation in anovulatory or oligo-ovulatory women after a low- dose step-up protocol with weekly increments of 25 international.

Microdose follicular phase gonadotropin-releasing hormone agonists (GnRH-a) compared with luteal phase GnRH-a for ovarian stimulation at in vitro fertilization5

Changes in circulating levels and ratios of angiopoietins during pregnancy but not during the menstrual cycle and controlled ovarian stimulation Amanda.

Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 μg) and ethinyl estradiol (15 μg) on ovarian activity Helen Sullivan,

Serum antimüllerian hormone levels are independently related to miscarriage rates after in vitro fertilization–embryo transfer Bruno Tarasconi, M.D.,

Reliability of automated volumetric measurement of multiple growing follicles in controlled ovarian hyperstimulation Frederic Lamazou, M.D., Elisangela.

Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin-releasing hormone antagonist administration

Clinical Assessment of Recombinant Human Follicle-Stimulating Hormone in Stimulating Ovarian Follicular Development Before In Vitro Fertilization fn1

René Ecochard, M. D. Ph. D. , Agnes Guillerm, M. D. , René Leiva, M. D

Serum luteinizing hormone levels are markedly increased and significantly correlated with Δ4-androstenedione levels in lean women with polycystic ovary.

Tomer Singer, M. D. , David H. Barad, M. D. , M. S

No evidence of the inactivating mutation (C566T) in the follicle-stimulating hormone receptor gene in Brazilian women with premature ovarian failure

Vaginally administered estroprogestinic decreases serum inhibin A and inhibin B levels and reduces endometrial thickness Stefano Luisi, M.D., Lavinia.

Effect of letrozole at 2. 5 mg or 5

Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis Rina Agrawal,

Anti-Müllerian hormone and inhibin B as predictors of pregnancy after treatment by in vitro fertilization/intracytoplasmic sperm injection Dorothea M.

Concentrations of inhibins and activin in women undergoing stimulation with recombinant follicle-stimulating hormone for in vitro fertilization treatment

Massimo Tartagni, M. D. , Luca Maria Schonauer, M. D

Fertility and Sterility

Assessment of luteinizing hormone level in the gonadotropin-releasing hormone antagonist protocol Georg Griesinger, M.D., Anja Dawson, M.D., Askan Schultze-Mosgau,

Comparison of basal follicle-stimulating hormone versus the clomiphene citrate challenge test for ovarian reserve screening Tarun Jain, M.D., Michael.

Hongxia Li, M. D. , Steven T Nakajima, M. D. , Jiangang Chen, M. D

A double-blind clinical trial comparing a fixed daily dose of 150 and 250 IU of recombinant follicle-stimulating hormone in women undergoing in vitro.

Uterorelaxing effects of vaginal progesterone: comparison of two methodologies for assessing uterine contraction frequency on ultrasound scans Jean-Marc.

Comparison of urinary and recombinant follicle-stimulating hormone in in vitro growth, maturation, and fertilization of mouse preantral follicles Giannina.

Circulating Bioactive and Immunoreactive Recombinant Human Follicle-Stimulating Hormone (Org 32489) After Administration to Gonadotropin-Deficient Subjects

CD11c+HLADR+ dendritic cells are present in human ovarian follicular fluid, and their maturity correlates with serum estradiol levels in response to gonadotropins

Predictive value of basal follicle-stimulating hormone concentrations in a general subfertility population Joris M van Montfrans, M.D., Annemieke Hoek,

Moderately elevated levels of basal follicle-stimulating hormone in young patients predict low ovarian response, but should not be used to disqualify.

Anuja Dokras, M. D. , Ph. D. , Antonia Habana, M. D. , Juan Giraldo, M

Effectiveness of cetrorelix for the prevention of premature luteinizing hormone surge during controlled ovarian stimulation using letrozole and gonadotropins:

Administration of gonadotropin-releasing hormone antagonist from day 1 of stimulation in in vitro fertilization Efstratios M Kolibianakis, M.D., Kostas.

Operative transvaginal hydrolaparoscopy for treatment of polycystic ovary syndrome: a new minimally invasive surgery Hervé Fernandez, M.D., Jean-Dominique.

Lower levels of inhibin A and pro-αC during the luteal phase after triggering oocyte maturation with a gonadotropin-releasing hormone agonist versus human.

First live birth after ovarian stimulation using a chimeric long-acting human recombinant follicle-stimulating hormone (FSH) agonist (recFSH-CTP) for.

Cem Fiçicioǧlu, M. D. , Tayfun Kutlu, M. D. , Elif Baglam, M. D

Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles David.

Microdose gonadotropin-releasing hormone agonist in the absence of exogenous gonadotropins is not sufficient to induce multiple follicle development

Defining the “sweet spot” for administered luteinizing hormone-to-follicle-stimulating hormone gonadotropin ratios during ovarian stimulation to protect.

Ovarian follicular volume and follicular surface area are better indicators of follicular growth and maturation, respectively, than is follicular diameter

Effect of obesity on recombinant follicle-stimulating hormone absorption: subcutaneous versus intramuscular administration Michael P Steinkampf, M.D.,

Day-5 inhibin B serum concentrations and antral follicle count as predictors of ovarian response and live birth in assisted reproduction cycles stimulated.

Ernesto Bosch, M. D. , Elena Labarta, M. D

Marijke Faas, Ph. D. , Annechien Bouman, M. D

Presentation transcript:

Luteal estradiol administration strengthens the relationship between day 3 follicle- stimulating hormone and inhibin B levels and ovarian follicular status Renato Fanchin, M.D., João Sabino Cunha-Filho, M.D., Luca Maria Schonäuer, M.D., Claudia Righini, M.D., Dominique de Ziegler, M.D., René Frydman, M.D. Fertility and Sterility Volume 79, Issue 3, Pages 585-589 (March 2003) DOI: 10.1016/S0015-0282(02)04757-X

FIGURE 1 Serum FSH (top panel), inhibin B (middle panel), and E2 (bottom panel) profiles during the first 3 days after E2 discontinuation (FD1, FD2, and FD3) in the E2-treated group. Both the progressive elevation in FSH and inhibin B levels, as well as the decrease in E2 levels, from FD1 to FD3 were statistically significant (open bars, P<.0001). Hormone levels on FD3 were significantly different as compared to controls (CD3, closed bars, *P<.0001). Fanchin. FSH and inhibin B elevation timed by E2. Fertil Steril 2003. Fertility and Sterility 2003 79, 585-589DOI: (10.1016/S0015-0282(02)04757-X)